A carregar...
Current options and future possibilities for the systemic treatment of hepatocellular carcinoma
Most hepatocellular carcinoma patients could not benefit from or experience disease recurrence after curative treatments. In 2007 sorafenib demonstrated efficacy in first line treatment of advanced hepatocellular carcinoma. After a decade of negative trials, in early 2019 we now have another tyrosin...
Na minha lista:
| Publicado no: | Hepat Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Future Medicine Ltd
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6571544/ https://ncbi.nlm.nih.gov/pubmed/31244990 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/hep-2019-0001 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|